The medicines agency AIFA authorised the mouth spray Sativex for adults with moderate to severe muscle stiffness from multiple sclerosis that other drugs had not controlled, if they improved during a trial period. Only hospital centres or neurologists could prescribe it, with a new prescription each time. The approval took effect on 1 May 2013.[1][2]
Listed for context. No score change is recorded for Italy here.
References
- Gazzetta Ufficiale — AIFA determination 387 of 9 April 2013, Sativex authorisation (published 30 April 2013)archived
- Cannabis: non solo fumoBernardo Parrella · Stampa Alternativa · 2014 · Il caso italiano — Cannabis Social Club e terapie collaborative
Checked. The date and the event were compared with a source that was read.